CYTOKINETICS, INCORPORATED Deferred Revenue
CYTOKINETICS, INCORPORATED (CYTK) had Deferred Revenue of $1.65 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-08-06
- 2026-06-30: Deferred Revenue, Current $1.65M.
- 2026-03-31: Deferred Revenue, Current $1.65M.
- 2025-12-31: Deferred Revenue, Current $1.61M.
- 2025-09-30: Deferred Revenue, Current $1.61M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2026-06-30 | $1.65M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.65M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $1.61M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.61M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.34M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $52.37M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $52.37M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-07 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-09 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 |
| 2018-03-31 | $4.51M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $9.57M 10-K · filed 2019-03-07 |
| 2017-09-30 | $9.57M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $7.94M 10-Q · filed 2017-08-04 |
| 2017-03-31 | $10.97M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $8.06M 10-K · filed 2018-03-05 |
| 2016-09-30 | $10.50M 10-Q/A · filed 2016-12-15 |
| 2016-06-30 | $13.56M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $15.91M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $20.86M 10-K · filed 2017-03-06 |
| 2015-09-30 | $21.37M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $20.99M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $19.94M 10-Q · filed 2015-05-04 |
| 2014-12-31 | $17.04M 10-K · filed 2016-03-03 |
| 2014-09-30 | $5.28M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $8.98M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $10.40M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $14.70M 10-K · filed 2015-03-06 |
| 2013-09-30 | $33.32M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $25.53M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $43.00K 10-Q · filed 2013-05-08 |
| 2012-12-31 | $76.00K 10-Q · filed 2013-05-08 |
| 2012-09-30 | $129.00K 10-Q · filed 2012-11-07 |
| 2011-06-30 | $263.00K 10-Q · filed 2011-08-04 |
| 2010-12-31 | $0.00 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |